Soloway M S, Hardeman S W, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M
Department of Baptist Memorial Hospital, Memphis, Tennessee.
Cancer. 1988 Jan 1;61(1):195-202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y.
Most patients with metastatic prostate cancer will have metastasis to bone. Such patients are best monitored by serial radionuclide bone scans. One hundred sixty six men with bone metastasis from prostate cancer who received androgen deprivation therapy had their pretreatment bone scans reviewed using a semiquantitative grading system based upon the extent of disease (EOD) observed on the scan. The EOD on the scan correlated with survival. The 2-year survival rates for EOD I to IV were 94%, 74%, 68%, and 40%, respectively. The survival of patients in categories EOD I and IV significantly differed from the other categories. Men with metastatic prostate cancer entered into trials designed to evaluate the impact of treatment on survival should be stratified based upon the EOD on the bone scan. This analysis also indicates that patients in the EOD IV category have a particularly poor prognosis and may be candidates for alternative treatments.
大多数转移性前列腺癌患者会发生骨转移。此类患者最好通过系列放射性核素骨扫描进行监测。166例接受雄激素剥夺治疗的前列腺癌骨转移男性患者，其治疗前的骨扫描采用基于扫描观察到的疾病范围（EOD）的半定量分级系统进行评估。扫描时的EOD与生存率相关。EOD I至IV级的2年生存率分别为94%、74%、68%和40%。EOD I级和IV级患者的生存率与其他级别显著不同。参与旨在评估治疗对生存率影响的试验的转移性前列腺癌男性患者，应根据骨扫描的EOD进行分层。该分析还表明，EOD IV级患者的预后特别差，可能是替代治疗的候选者。
